Caplin Steriles, a subsidiary of Caplin Point Laboratories (NSE:CAPLIPOINT, BOM:524742) has received final approval from the US Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for the Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution.
The drug (eye drops) is a generic therapeutic equivalent version of Abbvie Inc.'s reference-listed drug COMBIGAN, according to a Wednesday filing to the Indian stock exchanges.
Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution is used for the reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension.
As per IQVIATM estimates, Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution had sales of around $242 million for the 12 months ending December 2024 in the US.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.